Icalziss

Calcium chloride dihydrate, the active ingredient in Icalziss, is a calcium supplement presented as a sterile solution for extracorporeal use. It is employed to restore calcium levels and support cardiac and neuromuscular function in patients requiring electrolyte replenishment.\n\nGNH India supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis clinics worldwide.

Icalziss, a calcium supplement, acts on calcium homeostasis and electrolyte balance.\n\nHypocalcemia: restores serum calcium concentrations in patients with low calcium levels.\nCardiac arrest (calcium channel blockade): supports myocardial contractility during resuscitation.\nDialysis therapy: provides calcium during extracorporeal renal replacement procedures.\nHyperkalemia management: stabilises cardiac membranes when used alongside potassium‑lowering agents.

Calcium chloride dihydrate may cause a range of adverse reactions when administered extracorporeally.\n\nCommon Side Effects:\n- Flushing or sensation of warmth at the infusion site.\n- Nausea or mild gastrointestinal discomfort.\n- Transient hypotension during rapid infusion.\n- Mild muscle cramps or tingling sensations.\n\nSerious or Rare Side Effects:\n- Severe hypercalcaemia leading to cardiac arrhythmias.\n- Tissue necrosis or ulceration if the solution extravasates.\n- Respiratory distress or bronchospasm.\n- Life‑threatening cardiac arrest in patients with underlying conduction disorders.

When using Icalziss, clinicians should observe several safety measures.\n\nAssess serum calcium: obtain baseline calcium levels before administration.\nMonitor cardiac rhythm: continuous ECG monitoring during infusion.\nCheck renal function: adjust dosing in patients with impaired kidney function.\nAvoid extravasation: ensure secure intravenous access and proper line placement.\nStore at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Calcium chloride dihydrate can interact with several medications, requiring careful management.\n\nMajor Interactions (Avoid):\n- Digitalis glycosides: increased risk of arrhythmia.\n- Loop diuretics: may exacerbate calcium loss.\n- Bisphosphonates: reduced therapeutic effect.\n- Magnesium sulfate: antagonistic effect on calcium activity.\n\nModerate Interactions (Monitor Closely):\n- ACE inhibitors: monitor blood pressure for additive hypotensive effect.\n- Beta‑blockers: observe heart rate and contractility changes.